Sandler Laura Lee 4
4 · Oruka Therapeutics, Inc. · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
Oruka (ORKA) COO Laura Sandler Sells Shares, Exercises Options
What Happened
Laura Lee Sandler, Chief Operating Officer of Oruka Therapeutics (ORKA), exercised options to acquire 5,000 shares at $7.80 each (cost $39,000) and sold a total of 5,000 common shares in open-market transactions on July 1, 2026 for aggregate proceeds of about $472,079. The filing also shows a separate derivative disposition of 5,000 shares recorded at $0.00 (no proceeds). The exercise (buy) is a cash outlay; the open‑market sales are disposals—sales were executed under a pre-established trading plan.
Key Details
- Transaction date: 2026-07-01 (all reported transactions)
- Purchased (M/exercise): 5,000 shares @ $7.80 = $39,000 (acquired)
- Disposed (S/open market):
- 2,237 shares @ weighted avg $93.85 = $209,933 (prices ranged $93.29–$94.26)
- 2,263 shares @ weighted avg $94.75 = $214,410 (prices ranged $94.38–$95.19)
- 500 shares @ weighted avg $95.47 = $47,736 (prices ranged $95.40–$95.51)
- Total sales proceeds ≈ $472,079
- Additional derivative line: 5,000 shares reported disposed at $0.00 (M code) — filing includes a footnote about warrant vesting (see below).
- Sales were effected pursuant to a Rule 10b5-1 trading plan entered September 19, 2025 (footnote F1).
- Shares owned after the transactions: not specified in the data provided in your summary filing.
- Filing timeliness: reported as filed on 2026-07-01 (no late filing indicated in the provided data).
Context and plain-language notes
- The filing shows both an option exercise (acquisition) and same-day open-market sales of roughly the same number of shares. Exercising options is a purchase event; selling shares under a 10b5-1 plan is generally a preplanned sale and may be routine rather than an immediate signal about the insider’s view of the company.
- The M-coded disposition at $0.00 likely reflects a derivative conversion/settlement or similar non‑cash transaction; footnote F5 in the filing describes a warrant vesting schedule (1/4 on April 3, 2025 and monthly thereafter), which may relate to that line. The filing does not provide further explanation beyond the footnotes.
If you want, I can extract the exact price ranges and per‑trade breakdowns or check the original SEC filing for the post‑transaction beneficial ownership figure.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-07-01$7.80/sh+5,000$39,000→ 241,384 total - Sale
Common Stock
[F1][F2]2026-07-01$93.85/sh−2,237$209,933→ 239,147 total - Sale
Common Stock
[F1][F3]2026-07-01$94.75/sh−2,263$214,410→ 236,884 total - Sale
Common Stock
[F1][F4]2026-07-01$95.47/sh−500$47,736→ 236,384 total - Exercise/Conversion
Employee Warrant (right to buy)
[F5]2026-07-01−5,000→ 79,996 totalExercise: $7.80Exp: 2034-07-14→ Common Stock (5,000 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.29 to $94.26, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.38 to $95.19, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.40 to $95.51, inclusive.
- [F5]The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.